COVID-19 INFORMATION

IUPHAR’S RESPONSE to COVID-19

IUPHAR is responding to the current crisis by coordinating pharmacological resources worldwide, particularly the responses of the pharmacological community. Although to date most pharmacological studies regarding COVID-19 are limited to adults, we believe that in part it may be relevant for pediatric pharmacologists as well.

Download
Download IUPHAR's response to COVID-19 here
IUPHAR Response to COVID v5MS.pdf
Adobe Acrobat Document 179.5 KB

Key documents can be found on the  following websites:

  • Responses of the pharmacological community as well as information about COVID-19 research. This information will be continuously updated:

https://iuphar.org/coronavirus-news  

  • Pharmacological considerations regarding the COVID-19 Pandemic from the IUPHAR Clinical Division:

https://iuphar.org/wp-content/uploads/2020/05/IUPHAR-Clinical-Division-Considerations-in-the-Context-of-COVID-19-Pandemics.pdf

  • Information about drugs being currently proposed or assessed for treatment:

https://www.guidetopharmacology.org/coronavirus.jsp

  • An article on drug testing against SARS-CoV-2 is available in preprint for comments on Authorea "A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development":

https://doi.org/10.22541/au.158679935.58510327

Pediatric-pharmacological COVID-19 research

If you are involved in any pediatric-pharmacological COVID-19 research, please let us know at info@esdppp.org . We would be pleased to share the information via our website and our Linked-In channel.